Biology subjects

Fernando, A.

Publications and source records attributed to Fernando, A..

4 recordsLinked to original sources

bioRxiv2026

KRAKEN: A provenance-tracked knowledge graph for multiomic and wellness research

Existing general-purpose biomedical knowledge graphs tend to focus on disease mechanisms and drug repurposing, leaving multiomic and wellness-relevant content underrepresented. KRAKEN (Knowledge Research & Analysis Kit for Evidence Networks) addresses this gap by integrating existing graphs (including Translator KG Open, RTX-KG2, and ROBOKOP) with specialized sources such as RefMet, LIPID MAPS, NIH Common Data Elements, Polygenic Score Catalog, and derived wellness measures including biological age and biological BMI. The resulting graph spans ~15M nodes and ~113M edges across 62 entity types. KRAKEN adopts the Biolink Model as its semantic layer, ensuring compatibility with standardized resources emerging from the NIH NCATS Biomedical Data Translator program. A lightweight, modular build system rebuilds the full graph (including entity resolution), with peak memory consumption under 48 GB, and supports flexible inclusion or exclusion of sources, allowing the user to scope the graph to a domain of interest. Built-in analytical tools include multi-hop reasoning, subgraph extraction, text, vector and hybrid entity search, and enrichment analyses, all accessible through an interactive web interface, a REST API, and a Model Context Protocol server, the last enabling direct consumption by agentic and LLM-based systems. KRAKEN is freely available at https://app.krakenkg.com.

bioinformatics↗

bioRxiv2023

Identification of a Micropeptide Linked to Cancer Stem Cell Regulation and Chemoresistance

Short open reading frames encoding micropeptides (miPEPs) less than 100 amino acids in length have recently emerged as important regulators of diverse biological functions. However, the functional role of cancer-specific miPEPs in cancer progression and therapeutic response remains largely unexplored. Genome-wide association studies have identified an association of Iroquois (IRX) clusters with multiple cancer risk. In this study, we identified 17 miPEPs generated from IRX clusters in prostate, breast, endometrial, and ovarian cancers using SWATH-MS/MS-based proteomic analysis. We found that IRX4-derived miPEP, IRX4_PEP1, promotes prostate cancer (PCa) cell proliferation, migration, and invasion by interacting with heterogeneous nuclear ribonucleoprotein K (hnRNPK). Overexpression of IRX4_PEP1 leads to dysregulation of stem cell pathways by co-interaction with Catenin beta-1 (CTNB1) and upregulation of prominent PCa stem markers, resulting in docetaxel resistance in PCa. IRX4_PEP1 expression is significantly upregulated in prostate tumour tissues compared to normal and is positively correlated with disease aggressiveness. SIGNIFICANCEOur findings highlight the critical role of IRX4_PEP1 in regulating PCa stem cells and chemotherapy resistance and suggest it as a novel therapeutic target for the treatment of PCa. Moreover, IRX4_PEP1 expression can serve as a novel potential diagnostic and prognostic biomarker for PCa.

cancer biology↗

bioRxiv2019

Light-Activated Nanoscale Gas Vesicles Selectively Kill Tumor Cells

Protein-based nanobubbles such as halophilic archaeabacterial gas vesicles (GVs) represent a new class of stable, homogeneous nanoparticles with acoustic properties that allow them to be visualized by ultrasound (US) waves. To design GVs as theranostic agents, we modified them to respond to light, with a view to locally generate reactive oxygen species that can kill cancer cells. Specifically, up to 60,000 photoreactive chlorin e6 (Ce6) molecules were chemically attached to lysine {varepsilon}-amino groups present on the surface of each purified Halobacterium sp. NRC-1 GV. The resulting fluorescent NRC-1 Ce6-GVs have dimensions comparable to that of native GVs and were efficiently taken up by human breast [MCF-7] and human hypopharyngeal [FaDu-GFP] cancer cells as monitored by confocal microscopy and flow cytometry. When exposed to light, internalized Ce6-GVs were 200-fold more effective on a molar basis than free Ce6 at killing cells. These results demonstrate the potential of Ce6-GVs as novel and promising nanomaterials for image-guided photodynamic therapy.

cancer biology↗

bioRxiv2018

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

BackgroundThe risk of recurrence for endocrine-treated breast cancer patients persists for many years or even decades following surgery and apparently successful adjuvant therapy. This period of dormancy and acquired resistance is inherently difficult to investigate, previous efforts have been limited to in vitro or in vivo approaches. In this study, sequential tumour samples from patients receiving extended neoadjuvant endocrine treatment were characterised as a novel clinical model.\n\nMethodsConsecutive tumour samples from 62 patients undergoing extended (4-45 months) neoadjuvant aromatase inhibitor, letrozole, therapy were subjected to transcriptomic and proteomic analysis, representing before ([≤]0), early-on (13-120 days) and long-term (>120 days) neoadjuvant letrozole treatment. Patients with at least a 40% initial reduction in tumour size by 4 months of treatment were included. Of these, 42 patients with no subsequent progression were classified as \"dormant\", and the remaining 20 patients as \"acquired resistant\".\n\nResultsChanges in gene expression in dormant tumours begin early and become more pronounced at later timepoints. Therapy-induced changes in resistant tumours were common features of treatment, rather than being specific to resistant phenotype. Comparative analysis of long-term treated dormant and resistant tumours highlighted changes in epigenetics pathways including DNA methylation and histone acetylation. DNA methylation marks 5-methylcytosine and 5-hydroxymethylcytosine were significantly reduced in resistant tumours compared to dormant tissues after extended letrozole treatment.\n\nConclusionsThis is the first patient-matched gene expression study investigating long-term aromatase inhibitor-induced dormancy and acquired resistance in breast cancer. Dormant tumours continue to change during treatment whereas acquired resistant tumours more closely resemble their diagnostic samples. Global loss of DNA methylation was observed in resistant tumours under extended treatment. Epigenetic alterations may lead to escape from dormancy and drive acquired resistance in a subset of patients supporting a potential role for therapy targeted at these epigenetic alterations in the management of endocrine resistant breast cancer.

cancer biology↗